Neoantigens.unique

What if we could visualise how mutations change the surface of cancer cells? Explore what makes them distinct? It would enable us to identify the best possible targets and design medicines that specifically recognise and kill cancer cells.

At Imuno we broaden the repertoire of cancer-specific epitopes to lay the foundation for novel targeted therapies. It is our ambition to build a best-in-class artificial intelligence platform to accurately identify cancer-escape epitopes, and to grow our off-the-shelf portfolio of targeted therapies.

Our pipeline (soon)
Neoantigens

Rational design of targeted therapies.

Imuno is pioneering the power of machine learning to build a structure-based discovery engine to identify cancer-specific epitopes that can be exploited by novel therapeutic strategies. Our discovery engine not only identifies epitopes that are 100% unique to a patient’s tumor, it selects those that have the best properties for therapeutic targeting.

Our technology.platform 

Team.unique 

Founded by a pioneering scientist who embraced himself with leading experts in the biopharmaceutical industry. Imuno has the right skillset, and a team with decades of experience developing groundbreaking life-sciences companies. As such, Imuno is ready to build a successful biopharmaceutical company developing next-generation targeted therapies. 

Our team (soon)

Team.unique 

Update.news 

Loading blog posts...